24 May 2021 : Meta-Analysis
Relationship of Programmed Death-1 (PD-1) and Programmed Death Ligand-1 (PD-L1) Polymorphisms with Overall Cancer Susceptibility: An Updated Meta-Analysis of 28 Studies with 60 612 Subjects
Wenjing Zhang12BCDEF, Yuxuan Song34ABEF, Xiangcheng Zhang1ACEG*DOI: 10.12659/MSM.932146
Med Sci Monit 2021; 27:e932146
Table 4 Subgroup analyses based on cancer type.
| Genotype | Subgroup | n | Contrast model | OR (95% CI) | P | Test for heterogeneity | Analysis model | |
|---|---|---|---|---|---|---|---|---|
| I2 (%) | P | |||||||
| rs10204525 | Esophageal cancer | 4 | A vs G | 1.015 (0.862–1.195) | 0.859 | 77.40 | 0.004 | R |
| GA vs GG | 1.063 (0.796–1.419) | 0.679 | 63.70 | 0.041 | R | |||
| AA vs GG | 1.122 (0.749–1.681) | 0.576 | 77.70 | 0.004 | R | |||
| AA+GA vs GG | 1.068 (0.774–1.475) | 0.687 | 73.50 | 0.010 | R | |||
| AA vs AG+GG | 1.030 (0.832–1.274) | 0.787 | 71.90 | 0.014 | R | |||
| Breast cancer | 1 | A vs G | 0.891 (0.745–1.064) | 0.202 | . | . | R | |
| GA vs GG | 0.976 (0.640–1.488) | 0.910 | . | . | R | |||
| AA vs GG | 0.834 (0.549–1.267) | 0.395 | . | . | R | |||
| AA+GA vs GG | 0.898 (0.601–1.342) | 0.600 | . | . | R | |||
| AA vs AG+GG | 0.851 (0.674–1.074) | 0.174 | . | . | R | |||
| Gastric cancer | 1 | A vs G | 1.085 (0.871–1.351) | 0.021 | . | . | R | |
| GA vs GG | 1.417 (0.817–2.461) | 0.215 | . | . | R | |||
| AA vs GG | 1.380 (0.805–2.366) | 0.241 | . | . | R | |||
| AA+GA vs GG | 1.396 (0.825–2.360) | 0.213 | . | . | R | |||
| AA vs AG+GG | 1.033 (0.784–1.361) | 0.817 | . | . | R | |||
| rs2227981 | Breast cancer | 2 | C vs T | 1.219 (1.045–1.422) | 0.012 | 6.70 | 0.301 | R |
| TC vs TT | 1.081 (0.750–1.557) | 0.677 | 0.00 | 0.408 | R | |||
| CC vs TT | 1.309 (0.910–1.883) | 0.147 | 0.00 | 0.975 | R | |||
| CC+CT vs TT | 1.206 (0.852–1.707) | 0.291 | 0.00 | 0.750 | R | |||
| CC vs CT+TT | 1.301 (0.991–1.706) | 0.058 | 49.60 | 0.159 | R | |||
| Ovarian cancer | 2 | C vs T | 0.639 (0.241–1.694) | 0.368 | 94.60 | R | ||
| TC vs TT | 0.304 (0.053–1.756) | 0.183 | 88.00 | 0.004 | R | |||
| CC vs TT | 0.358 (0.063–2.054) | 0.249 | 88.50 | 0.003 | R | |||
| CC+CT vs TT | 0.336 (0.058–1.942) | 0.223 | 89.00 | 0.003 | R | |||
| CC vs CT+TT | 0.769 (0.390–1.516) | 0.449 | 82.90 | 0.015 | R | |||
| rs2227982 | Esophageal cancer | 4 | C vs T | 0.982 (0.914–1.056) | 0.623 | 10.20 | 0.342 | F |
| TC vs TT | 1.095 (0.966–1.241) | 0.154 | 0.00 | 0.813 | F | |||
| CC vs TT | 0.961 (0.831–1.112) | 0.592 | 15.10 | 0.316 | F | |||
| CC+CT vs TT | 1.049 (0.932–1.181) | 0.424 | 0.00 | 0.613 | F | |||
| CC vs CT+TT | 0.907 (0.805–1.022) | 0.108 | 11.80 | 0.334 | F | |||
| Breast cancer | 2 | C vs T | 1.173 (1.040–1.322) | 0.010 | 0.00 | 0.599 | F | |
| TC vs TT | 1.012 (0.823–1.245) | 0.908 | 0.00 | 0.758 | F | |||
| CC vs TT | 1.379 (1.081–1.758) | 0.010 | 0.00 | 0.734 | F | |||
| CC+CT vs TT | 1.120 (0.921–1.361) | 0.257 | 0.00 | 0.980 | F | |||
| CC vs CT+TT | 1.375 (1.126–1.679) | 0.002 | 0.00 | 0.536 | F | |||
| rs2890658 | Non-small cell lung | 2 | A vs C | 0.609 (0.477–0.777) | 0.000 | 5.20 | 0.304 | F |
| CA vs CC | 0.777 (0.252–2.398) | 0.661 | 0.00 | 0.817 | F | |||
| AA vs CC | 0.465 (0.155–1.397) | 0.172 | 0.00 | 0.662 | F | |||
| AA+AC vs CC | 0.503 (0.167–1.510) | 0.221 | 0.00 | 0.668 | F | |||
| AA vs AC+CC | 0.589 (0.454–0.765) | 0.000 | 0.00 | 0.345 | F | |||
| Hepato-cellular carcinoma | 2 | A vs C | 1.358 (1.006–1.833) | 0.046 | 0.00 | 0.629 | F | |
| CA vs CC | 1.195 (0.430–3.323) | 0.733 | 0.00 | 0.380 | F | |||
| AA vs CC | 1.648 (0.612–4.436) | 0.323 | 0.00 | 0.361 | F | |||
| AA+AC vs CC | 1.516 (0.566–4.065) | 0.408 | 0.00 | 0.362 | F | |||
| AA vs AC+CC | 1.405 (1.002–1.970) | 0.049 | 0.00 | 0.794 | F | |||
| rs36094323 | Esophageal cancer | 3 | G vs A | 1.036 (0.893–1.202) | 0.639 | 61.80 | 0.073 | R |
| AG vs AA | 1.041 (0.893–1.214) | 0.608 | 0.00 | 0.960 | F | |||
| GG vs AA | 0.942 (0.789–1.125) | 0.510 | 0.00 | 0.436 | F | |||
| GG+GA vs AA | 1.008 (0.872–1.165) | 0.917 | 0.00 | 0.720 | F | |||
| GG vs GA+AA | 1.024 (0.810–1.295) | 0.843 | 68.90 | 0.040 | R | |||
| Ovarian cancer | 2 | G vs A | 0.727 (0.523–1.012) | 0.059 | 64.70 | 0.092 | R | |
| AG vs AA | 0.695 (0.538–0.897) | 0.005 | 0.00 | 0.673 | F | |||
| GG vs AA | 0.615 (0.459–0.823) | 0.001 | 61.80 | 0.106 | F | |||
| GG+GA vs AA | 0.666 (0.523–0.847) | 0.001 | 0.00 | 0.333 | F | |||
| GG vs GA+AA | 0.689 (0.397–1.196) | 0.185 | 65.90 | 0.087 | R | |||
| rs4143815 | Gastric cancer | 2 | C vs G | 0.708 (0.307–1.630) | 0.417 | 92.90 | R | |
| GC vs GG | 0.449 (0.185–1.089) | 0.077 | 73.90 | 0.050 | R | |||
| CC vs GG | 0.498 (0.132–1.878) | 0.303 | 87.00 | 0.006 | R | |||
| CC+CG vs GG | 0.473 (0.162–1.384) | 0.172 | 83.80 | 0.013 | R | |||
| CC vs CG+GG | 0.815 (0.348–1.911) | 0.638 | 85.20 | 0.009 | R | |||
| Hepato-cellular carcinoma | 2 | C vs G | 0.736 (0.440–1.233) | 0.245 | 81.50 | 0.020 | R | |
| GC vs GG | 0.422 (0.279–0.639) | 0.000 | 0.00 | 0.795 | R | |||
| CC vs GG | 0.459 (0.213–0.991) | 0.047 | 63.50 | 0.098 | R | |||
| CC+CG vs GG | 0.425 (0.288–0.628) | 0.000 | 0.00 | 0.353 | R | |||
| CC vs CG+GG | 0.864 (0.405–1.844) | 0.706 | 81.00 | 0.022 | R | |||
| rs7421861 | Esophageal cancer | 4 | T vs C | 1.000 (0.784–1.276) | 0.999 | 87.00 | R | |
| TC vs CC | 1.179 (0.995–1.396) | 0.057 | 0.00 | 0.770 | F | |||
| TT vs CC | 1.133 (0.760–1.689) | 0.541 | 61.00 | 0.053 | R | |||
| TT+CT vs CC | 1.169 (0.995–1.374) | 0.058 | 30.00 | 0.232 | F | |||
| TT vs CT+CC | 0.984 (0.735–1.317) | 0.913 | 83.00 | 0.001 | R | |||
| Breast cancer | 2 | T vs C | 0.960 (0.784–1.175) | 0.692 | 42.10 | 0.189 | R | |
| TC vs CC | 1.183 (0.730–1.917) | 0.494 | 0.00 | 0.923 | F | |||
| TT vs CC | 1.123 (0.701–1.798) | 0.630 | 0.00 | 0.701 | R | |||
| TT+CT vs CC | 1.169 (0.995–1.374) | 0.586 | 0.00 | 0.807 | F | |||
| TT vs CT+CC | 0.931 (0.729–1.189) | 0.565 | 46.10 | 0.173 | R | |||